Atricure, Inc.

  • Earnings Score
  • Moat Score
  • Safety Score
  • Market Cap $1.80B
  • PE -40
  • Debt $64.67M
  • Cash $122.72M
  • EV $1.74B
  • FCF $745.00K

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings-$44.70M
EBIT-$40.01M
ROE-10%
ROA-7%
FCF$745.00K
Equity$460.97M
Growth Stability1
PE-40.34
PEG-731.78
PB3.91
P/FCF2.42K
P/S3.87
Price/Cash0.07
Debt/Equity0.14
Debt/FCF86.81
Net Margins-10%
Gross Margins75%
Op. Margins-9%
Earnings CAGR0%
Sales Growth YoY17%
Sales Growth QoQ7%
Sales CAGR14%
Equity CAGR17%
Earnings Stability0
Earnings Growth YoY59%
Earnings Growth QoQ98%
Earnings CAGR 5Y0%
Sales CAGR 5Y20%
Equity CAGR 5Y7%
Earnings CAGR 3Y19%
Sales CAGR 3Y19%
Equity CAGR 3Y1%
Market Cap$1.80B
Revenue$465.31M
Assets$609.33M
Total Debt$64.67M
Cash$122.72M
Shares Outstanding46.97M
EV1.74B
Earnings Score6%
Moat Score6%
Safety Score73%
Final Score28%
Working Capital194.4M
Current Ratio3.65
Gross Profit$347.52M
Shares Growth 3y1%
Equity Growth QoQ-1%
Equity Growth YoY-1%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
AtriCure Inc is a innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States.

SEC Filings

Direct access to Atricure, Inc. (ATRC) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2024
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2022
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Atricure, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Atricure, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 0%
Stability 0%
loading chart...

Atricure, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Atricure, Inc..

= $7.4M
012345678910TV
fcf$745K$745K$745K$745K$745K$745K$745K$745K$745K$745K$745K$7.5M
DCF$677K$616K$560K$509K$463K$421K$382K$348K$316K$287K$2.9M
Value$7.4M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024TTM
Net Margins-21%-21%-15%-10%-15%-23%18%-14%-8%-10%-10%
ROA--11%-9%-5%-6%-6%9%-7%-4%-7%-7%
ROE--20%-17%-8%-14%-12%10%-10%-7%-10%-10%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024TTM
Debt over FCF--1.78-2.48-5.51-2.14-2.65-2.55-1.68-8.486.8186.81
Debt over Equity00.240.240.230.240.160.120.140.140.140.14
Growth Stability----------1

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024CAGR 5Y
Revenue YoY growth-20%13%15%14%-11%33%20%21%17%20%
Earnings YoY growth-23%-19%-21%67%37%-204%-193%-34%47%0%
Equity YoY growth--10%-4%55%-1%67%17%-6%2%-1%7%
FCF YoY growth-7%-33%-32%170%-10%-6%66%-81%-110%-